Discontinued — last reported Q3 '17
Deferred Tax Liabilities
Bristol-Myers Squibb Deferred Tax Liabilities decreased by 8.9% to $225.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 47.7%, from $430.00M to $225.00M. Over 4 years (FY 2020 to FY 2024), Deferred Tax Liabilities shows a downward trend with a -48.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates higher future tax obligations, while a decrease suggests the settlement or reversal of these temporary differences.
Detailed definition
Deferred tax liabilities represent the anticipated future tax payments resulting from temporary differences between the...
Peer comparison
Common in capital-intensive industries where accelerated depreciation for tax purposes creates significant timing differences.
deferred_tax_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.93B | $4.96B | $4.50B | $3.81B | $3.03B | $2.88B | $2.17B | $1.57B | $751.00M | $399.00M | $338.00M | $442.00M | $461.00M | $430.00M | $369.00M | $276.00M | $247.00M | $225.00M |
| QoQ Change | — | +0.5% | -9.2% | -15.4% | -20.3% | -5.0% | -24.8% | -27.6% | -52.1% | -46.9% | -15.3% | +30.8% | +4.3% | -6.7% | -14.2% | -25.2% | -10.5% | -8.9% |
| YoY Change | — | — | — | — | -38.5% | -41.9% | -51.9% | -58.8% | -75.2% | -86.2% | -84.4% | -71.8% | -38.6% | +7.8% | +9.2% | -37.6% | -46.4% | -47.7% |
Deferred Tax Liabilities at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's deferred tax liabilities?
- Bristol-Myers Squibb (BMY) reported deferred tax liabilities of $225.00M in Q3 2025.
- How has Bristol-Myers Squibb's deferred tax liabilities changed year-over-year?
- Bristol-Myers Squibb's deferred tax liabilities decreased by 47.7% year-over-year, from $430.00M to $225.00M.
- What is the long-term trend for Bristol-Myers Squibb's deferred tax liabilities?
- Over 4 years (2020 to 2024), Bristol-Myers Squibb's deferred tax liabilities has grown at a -48.9% compound annual growth rate (CAGR), from $5.41B to $369.00M.
- What does deferred tax liabilities mean?
- Future tax obligations resulting from timing differences between accounting and tax reporting.